Related Experiment Videos
[Demethyl-vancomycin in treatment of resistant staphylococcal infections. A clinical evaluation]
1Institute of Antibiotics, Hua Shan Hospital, Shanghai Medical University.
Abstract:
77 patients with serious resistant staphylococcal infections, including septicemia, lower respiratory infection, intraabdominal infection, skin and soft tissue infections and urinary tract infection, were treated with demethyl-vancomycin. 82% of the organisms were methicillin-resistant. Most of the patients had severe underlying diseases and were immunocompromised hosts. The infections were serious. The clinical efficacy rate was 73% and the bacteria clearance rate 68%. Mild adverse reactions happened in 11% of the patients and no obvious nephrotoxicity was noted. MIC90 of demethyl-vancomycin against staph. aureus was 2 micrograms/ml. All isolates in this study were highly susceptible to the drug. Demethyl-vancomycin was found more active against staphylococcus than the other 16 antibacterial agents, which are commonly used in this country. The indication and the use of the drug were discussed.
Insights
Demethyl-vancomycin effectively treated serious resistant staphylococcal infections in 77 patients, including methicillin-resistant strains. This antibiotic showed high efficacy and low toxicity, offering a promising option for challenging infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Context:
- Serious staphylococcal infections pose a significant clinical challenge, particularly those caused by methicillin-resistant strains.
- Immunocompromised patients and those with severe underlying conditions are at higher risk for these difficult-to-treat infections.
- Existing treatments may have limitations in efficacy or safety profiles for certain patient populations.
Purpose:
- To evaluate the clinical efficacy and safety of demethyl-vancomycin in treating serious resistant staphylococcal infections.
- To assess the antimicrobial activity of demethyl-vancomycin against Staphylococcus aureus, including methicillin-resistant isolates.
- To compare the activity of demethyl-vancomycin with other commonly used antibacterial agents.
Summary:
- A study involving 77 patients with serious resistant staphylococcal infections (including septicemia, respiratory, intraabdominal, skin, and urinary tract infections) was conducted.
- 82% of the staphylococcal isolates were methicillin-resistant, and most patients were immunocompromised with severe underlying diseases.
- Demethyl-vancomycin demonstrated a 73% clinical efficacy rate and a 68% bacteria clearance rate, with mild adverse reactions in 11% and no significant nephrotoxicity.
Impact:
- Demethyl-vancomycin exhibits potent activity against Staphylococcus aureus (MIC90 = 2 µg/mL), with all isolates showing high susceptibility.
- The drug was found to be more active against staphylococci compared to 16 other commonly used antibacterial agents.
- These findings suggest demethyl-vancomycin is a viable and potentially superior therapeutic option for managing severe staphylococcal infections, especially in resistant cases.